Havrix Junior (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Havrix Junior is indicated for the active immunisation of children against hepatitis A infection.

• Primary prophylaxis for hepatitis A in children according to recommended immunisation schedules.
• Administration as part of a two‑dose series, typically spaced 6–12 months apart.
• Use in travelers to regions where hepatitis A is endemic, when age‑appropriate.
• Supplemental protection for children with underlying liver disease who are at higher risk.
• May be given to children who have not previously received a hepatitis A vaccine.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines. These reactions are generally self‑limiting and resolve without medical intervention.

Common

• Mild pain, redness or swelling at the injection site.
• Low‑grade fever within 24 hours after vaccination.
• Transient headache or fatigue.
• Mild gastrointestinal discomfort such as nausea.
• Muscle aches or mild arthralgia.
• Transient rash or mild itching.

Serious

• Allergic reactions ranging from urticaria to anaphylaxis.
• Neurologic events such as Guillain‑Barré syndrome, reported rarely.

Before administering Havrix Junior, healthcare providers should review the following precautions to ensure safe use in pediatric patients.

• Defer vaccination in children with a known severe allergy to any vaccine component, including aluminium salts.
• Postpone dosing in individuals experiencing moderate or severe acute illness, especially fever.
• Assess prior hepatitis A vaccination history to avoid unnecessary repeat dosing.
• Consider the limited safety data in pregnancy; vaccination is generally avoided unless benefits outweigh risks.
• Monitor for signs of anaphylaxis for at least 15 minutes after injection.

Havrix Junior may interact with other agents; the following considerations are recommended when co‑administering medications or vaccines.

Avoid

• Concurrent administration with live viral vaccines is generally avoided to prevent potential immune interference.
• Do not give Havrix Junior to children receiving immunoglobulin therapy for hepatitis A prophylaxis, as it may reduce vaccine efficacy.

Use with caution

• Concurrent use of immunosuppressive drugs (e.g., corticosteroids) may diminish antibody response; timing should be coordinated.
• Antipyretics such as acetaminophen can be used to manage post‑vaccination fever, but routine prophylactic use may blunt immune response.
• If the child is on antiretroviral therapy, monitor hepatitis A antibody titres to confirm adequate seroconversion.